Aptar Q3 profit falls on Russia deconsolidation charge
Overview
Drug delivery and dispensing firm's Q3 sales rose 6%, beating analyst expectations
Adjusted EPS for Q3 was $1.52, beating analyst expectations
Reported EPS fell to $0.51 due to Russian subsidiary deconsolidation
Outlook
Aptar sees Q4 2026 adj EPS between $1.39 and $1.47
Company expects full-year results supported by Pharma growth, especially in consumer healthcare and injectables
Closures segment expected to see increased demand, driven by beverage technology innovation
Result Drivers
RUSSIAN DECONSOLIDATION - A government decree drove a $60.4 mln after-tax charge, cutting reported EPS by $0.94
PHARMA SEGMENT - Co said growth in central nervous system, pulmonary, injectables and consumer healthcare therapies drove Pharma segment sales
BEAUTY DEMAND - Increased demand for prestige fragrance dispensing, color cosmetics and hair care applications boosted Beauty segment sales
CLOSURES INNOVATION - Strong demand for beverage dispensing closures, bottled water, concentrates and condiments drove Closures segment growth
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $1.02 bln | $984.44 mln (7 Analysts) |
Q3 Adjusted EPS | Beat | $1.52 | $1.47 (8 Analysts) |
Q3 EPS | $0.51 | ||
Q3 Net Income | $33 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the non-paper containers & packaging peer group is "buy"
Wall Street's median 12-month price target for AptarGroup, Inc. is $154.78, about 18.5% above its October 29 closing price of $130.64
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago
Reuters Recommended Reads
Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook
Oct 29 - Ligand Pharmaceuticals Q3 royalty revenue jumps 51%
Oct 29 - Phathom Pharmaceuticals Q3 revenue rises 71%
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)